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 Antibiotics are recent advancements of medical technology, but their misuse and overuse 
have given rise to a variety of problems related to bacteria evolving resistance to these miracle 
drugs.  Unlike other medicinal drugs, antibiotics usage needs to be properly cared via the ideas of 
antibiotic stewardship for preserving their effectiveness for all members of the public, otherwise 
currently available drugs will lose their ability to combat illnesses.  The supply shortage of viable 
antibiotic agents is also heightened by the expensive nature of conducting research and 
development necessary to identify new sources, and the economic unwillingness of most 
pharmaceutical companies to invest towards working on finding these new antimicrobials.  
Continuing down this path would lead to a post-antibiotic world that would not be favorable to 
the modern lifestyle of humankind.  However, many opportunities still exist for working to 
preserve the efficacy of current antibiotics while supporting investments to develop new 
antibiotics, and this thesis highlights a number of suggestions for how people can work together 
towards ensuring that antibiotic agents are properly handled and cared for going into the future 
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Working Around the Impending Antibiotic Crisis 
Introduction to Modern Antibiotics 
 Antibiotics as humanity presently understands them were developed in the last 100 years 
and are considered to be a medicinal “miracle drug” or “wonder drug” due to their capabilities 
for fighting against historically dangerous infectious diseases.  Even though ancient humankind 
had been aware of the capabilities that certain herbs had in treating against diseases and passed 
this knowledge down through traditional medicine techniques, it was only relatively recently that 
Paul Ehrlich and Alexander Fleming were able to devise and implement the scientific methods 
that comprise modern methods for isolating antibiotic agents (Aminov 2010).  Ehrlich utilized a 
systematic approach towards identifying a drug that would only target syphilis bacteria and leave 
normal, healthy cells alone and unaffected, thus paving the way for pharmaceutical companies to 
find “magic bullet” agents for other bacterial diseases as well.  Fleming, credited with 
discovering penicillin from examining the inhibition zones of Penicillium mold on agar plates, 
dedicated many years of research to develop an analysis method for purifying and stabilizing the 
active parts of antibiotic agents in order to include them in pharmaceutical drugs for easier 
distribution across the general public.  Through a combination of their groundbreaking work, the 
pharmaceutical industry began to discover and manufacture a variety of antibiotic drugs for 
treating some common infections found among humans, and helped spread the prevalence of 
antibiotics around the world as an easy solution for the general public. 
 With the advent of common antibiotic drugs being produced came a whole set of 
improvements to the quality of other medical treatments.  Some fields of medicine, such as 
surgery, picked up antibiotic usage to help patients successfully recover after the procedure 
without developing undesirable diseases, while a number of other important fields, including 
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cancer chemotherapy or organ transplants and those working with patients having suppressed 
immune systems, came to require having available antibiotic prescriptions for ensuring that the 
patient does not become ill during their scheduled procedure (Gandra 2014).  As a result, 
antibiotics have become embedded into modern society as one integral piece of medical 
technology that supports the capability for many other lifesaving techniques to be successfully 
performed with limited probability of infection-related side effects occurring in the patient. 
 Beyond simply being developed for human use, there were other experiments conducted 
by Thomas Jukes that showed young chickens fed with remnants of manufacturing antibiotics 
would gain approximately double the weight compared to chicks that were not, and that this 
difference was primarily due to the minor presence of antibiotic agents left among the remnants.  
The agricultural industry was ecstatic over what, on the surface, appeared to be a very cheap feed 
product to introduce additional nutrients for their animals.  Farmers did not see any downsides to 
including antibiotic remnants in animal feed, so as a result a new industry of “growth-promoter 
antibiotics” were developed targeted at suppressing diseases in farm animals and allowing them 
to grow large much quicker than before the introduction of antibiotics (The Inquiry 2016).  This 
has led to increased meat production from farm animals that humans have gladly consumed on a 
large scale throughout the years since, but the resultant impacts have shown up through increased 
prevalence of antibiotic-resistant bacteria strains around the world as well as whole farms losing 
their value when an infection is able to take hold and spread despite the antibiotic materials being 




Issues of Resistance and Compounding Factors 
 The major problem with the extensive usage of antibiotics is that the microbes they are 
meant to fight will build up some form of resistance against those very antibiotic agents due to 
selective pressures over time.  This is not considered unusual for the natural evolutionary 
processes, but the large quantities of antibiotics being used has driven the rise of major antibiotic 
resistance problems and corresponding superbugs such as methicillin-resistant Staphylococcus 
aureus (MRSA) and other infections common to the over-sterilized environment of hospitals.  It 
should be noted at this point that while evolution is often considered to be a slow process 
occurring by accumulating minor genetic changes through multiple generations, bacteria have a 
very short lifespan compared to humans and thus can easily progress through multiple 
generations and accumulate the corresponding opportunities to develop resistance-supportive 
genetic changes in a matter of years.  Even Fleming had acknowledged and warned about the 
potential of antibiotic resistance from the public abusing and overusing penicillin in 1946 
(Aminov 2010; Bartlett 2013), but his warning then went ignored and similar warnings about 
superbugs in recent years have not yet lead to many meaningful policy changes.  When 
considered by itself, the modern prevalence of antibiotic resistance probably would not be as 
much of a major issue if new classes of antibiotics were continuously being discovered to 
counteract the microbial development of resistance genes.  However, in the current economy 
many companies believe that new antibiotics are too difficult to find and are also not worth the 
monetary investment required to conduct the research and development of additional antibiotic 
agents, leading to a small variety of regulated antibiotic drugs that now remain capable of 
treating what are otherwise considered minor illnesses and bacterial diseases instead of a well-
maintained supply of targeted options. 
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 Unlike other medicinal drugs, antibiotics are unique in that one person’s usage of these 
agents affects how another person may respond to the same drugs due to the potential for 
microbes to develop resistance and transfer this resistance to other bacteria – necessitating 
extreme care to maintain their continued effectiveness, as even one individual’s personal 
behavioral patterns may contribute to containing or spreading antibacterial resistance (Aminov 
2010).  This comes in part due to the overzealousness of pharmaceutical companies wanting to 
sell more drugs and increase profits, which is understandable for companies trying to make 
money on their original investment into developing the antibiotic drug.  However, it also arises 
from doctors prescribing cocktails of multiple broad-spectrum antibacterial drugs against 
infections that are primarily caused from a narrow set of specific bacteria (Spellberg 2010).  
With this unnecessary overuse of precious antimicrobial agents when one targeted antibiotic 
could suffice, the bacteria are given many more opportunities to develop resistance against the 
current supply of antibiotics and driving humankind closer to relying solely on carbapenems, an 
antibiotic that targets Gram-negative bacteria and is reserved for cases when all other available 
drugs fail (Gandra 2014), and other “last-resort” drugs as a means of preventing illnesses. 
 A correlated factor here is the idea that patients who get sick and see their primary care 
physician are often instructed to complete a full course of antibiotics even if their symptoms 
resolve, since recurrent infections are caused by distinct bacteria strains rather than a relapse of 
the original antibiotic-treated strain (Spellberg 2016).  While the idea of ensuring the disease has 
been cured may be sound, the continued use of antibiotics after the body shows recovery do 
increase the evolutionary pressures on remaining bacteria to develop resistance and further 
increases the problems arising from trying to preserve the effectiveness of last-resort antibiotics 
(Aminov 2010).  The historical heuristics supporting the instructions for requiring completion of 
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a full antibiotic treatment were aimed at the idea of ensuring the illness has been cured, but 
modern science as a whole focuses on having evidence to build up drug use guidelines.  This 
suggests there exist opportunities where medical practices and standards can be improved with 
regards to applying antimicrobial agents for treating regular diseases, and instead could be 
supplanted by an evidence-based policy. 
 Antibiotics are considered magic bullets that could target the bacteria they are effective 
against, but the bacteria’s continued adaptations and population dynamics allow them to 
eventually resist the very drugs that people believed would work on them.  The very nature of 
evolution and natural selection drives bacteria that are better suited to changing environmental 
factors to proliferate as generations pass, and with the vast usage of present antibiotics around 
the world much of the bacteria’s environment consists of trying to survive against these 
antibacterial agents (Aminov 2010).  They also operate on a population-wide network with 
capabilities of signaling other bacterial cells and transferring genes between each other, though 
many parts of these intra-cellular interactions are still not fully understood by scientists (The 
Inquiry 2016; Merriman 2016).  It comes as no surprise then that in combination with their short 
lifespans, as previously mentioned, bacteria are rapidly communicating resistance genes among 
each other and allowing the spread of antibiotic resistance to occur with worldwide prevalence in 
only a number of years. 
 As a whole, the pharmaceutical industry had already isolated many of the “easier” 
sources of antibiotic agents by the 1960s, making completely new sources difficult to identify 
(The Inquiry 2016; Spellberg 2015).  This is especially true for the class of Gram-negative 
bacteria, which is quite worrying for scientists because these are the forms of bacteria already 
resistant to natural antibody defenses and are generally considered more able to develop 
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antibiotic resistance and spread these genes.  One related factor compounding the severity of this 
issue is due to strict FDA regulations on what can likely be approved for clinical trials of 
potential antibiotic drugs in simple cases, leaving clinicians uncertain about using new 
antibiotics in relatively complex infections (Spellberg 2010).  Even in cases of approved 
antibiotics, new drugs developed are primarily modified forms of previously-discovered agents 
and not novel cases as was common during the 1950s explosion of antibiotics research (Aminov 
2010).  This limits the potential effectiveness of these new drugs to treating similar cases as 
those already being treated with current market antibiotics rather than developing them to attack 
more difficult infections like MRSA, so the bacteria have relatively fewer evolutionary jumps to 
mutate through before they will find a suitable resistance gene for the new antibiotic. 
 Beyond the issues of bacteria evolving resistance to available antibacterial agents, the 
current market is unfavorable towards supporting research into new antibiotics.  From an 
economical perspective, companies no longer see any reasonable incentive to invest in 
discovering new antibiotics.  Without any outside incentives for pursuing antibiotic development, 
the net present value to a company considering the option of investing towards a new antibiotic 
is a $50 million loss compared to the typical investment that the company could pursue for other 
medicinal therapies (Bartlett 2013; Spellberg 2015).  This means that over the long run the 
company believes they would be losing out on the value of $50 million dollars today by working 
on antibiotic-related projects.  This is largely due to the relatively low sales prices for short 
antibiotic treatments consumed by a patient, as well as an extended length of time necessary to 
conduct the requisite research and complete regulatory clinical trials for new antibacterial agents 
before any sales can be made on a working antibiotic drug.  The impact of this extended length 
of research and development time is compounded by the fact that due to inflation money loses its 
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value as time passes, so a few hundred million dollars of future antibiotic sales may only be 
worth tens of million dollars in today’s value.  This projected return is often lower than the 
potential of developing other drugs, so many pharmaceutical companies end up making an 
economic decision of foregoing any work on the research and development process integral to 
finding new agents for treating infections (Bartlett 2013).  Antibiotic research and development 
also has to compete with the opportunities of other medicines providing long-term therapies for 
cancer and similar lifelong illnesses, which can easily generate many thousands of dollars from 
one course of treatment for a single patient and often compute to corresponding net present 
values of over $1 billion gain.  According to a cost analysis comparison, antibiotics are meant to 
be inexpensive treatments for short-term diseases while other drugs can be sold as expensive 
therapies for the rest of a patient’s life, so to a pharmaceutical company the potential economic 
value of antibiotics would at best only be derived from sacrificing the profits of other more 
lucrative drugs, and even then only if they truly wish to support the continued capabilities of 
antibacterial agents.  There is simply no rational economic reason for companies to lose money 
for a chance to discover the next antibacterial drug when they could potentially gain billions by 
developing the next medicine for extended treatment, and that has driven most pharmaceutical 
companies out of the antibiotic market in pursuit of long-term medicines. 
 Antibiotic resistance is also expensive to society as a whole, not just through costs related 
to developing new drugs as current ones lose their efficacy.  Healthcare costs that could be 
linked to hospital-acquired bacteria, which are often some of the most resistant strains in the 
world yet are not often discussed with the general public, have been estimated over $2 billion per 
year in the US alone – this is more than the annual spending for influenza, a virus the public is 
consciously aware of and actively develops annual vaccines for prevention (Aminov 2010).  
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Additionally, the patients who are forced to stay in the hospital for extended lengths of time as a 
result of such infections will forego earnings during the extended stay but also likely require 
additional post-discharge care to minimize the possibilities of complications leading to deaths 
and other illnesses, with estimates from the year 2000 suggesting these losses may easily run 
over $55 billion (Gandra 2014). 
 
Preventing a Post-Antibiotic World 
 Within the current framework of understanding microbial infections and antibiotic agents, 
it may seem like a major crisis looms on the horizon leading to a post-antibiotic world due to the 
multitude of issues previously discussed.  However, there are still many opportunities for 
continuing forward and maintaining the power of antimicrobial treatments that humans have 
come to take for granted.  It simply requires a concerted effort of people across disciplines and 
the general public at large working together towards a common goal, namely one aimed to 
revitalize efforts to discover and develop new treatments while preserving the efficacy of current 
antibiotic drugs.  Towards this goal, I shall suggest a number of ideas which may help to prevent 
or at worst delay the oncoming post-antibiotic scenario. 
 The first set of ideas is focused on preserving the efficacy of current antibiotic drugs.  
One major factor is the over-prescription of these drugs to people who would not actually benefit 
from using them.  Since people had hailed antibiotics as miracle drugs, they had often come to 
believe that any sickness they encounter can be cured or treated by taking some antibiotics – but 
this is often not the case, especially with antibiotic agents having no effect for viral infections.  
The public needs to be better educated about proper usage of antibiotics and work with doctors 
and physicians to understand why their particular sickness might not be treated with antibiotics, 
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thus minimizing inappropriate human usage of these valuable drugs.  This education can come 
through online advertisement campaigns and through other channels likely to reach a majority of 
the public in a manner similar to the anti-tobacco campaign, and should focus on working with 
primary care physicians for differentiating bacterial infections, such as E. coli or strep throat 
which is caused by Streptococcal bacteria, from viral diseases like the common cold and 
influenza.  It should also include helpful tips of individual practices most likely to minimize and 
prevent diseases from infecting members of the public such as the restroom handwashing signs, 
thereby applying the education idea along two approaches for reducing the usage of antibiotics.  
Although diagnostic technologies for distinguishing bacteria from viruses are already used in 
medical facilities, engineering advancements could help bring preliminary screening tools into 
public use alongside the education campaigns and reemphasize how antibiotics would not help 
treat the common cold affecting their child.  Other studies have shown that peer pressure among 
doctors can serve as an additional safeguard against over-prescribing antibiotics to a demanding 
public (Merriman 2016).  With commitments to sensibly serving prescriptions and including 
warnings in cases where antibiotics may not be effective, doctors and physicians become more 
willing to discuss disease details with their patients and reinforce the public education campaigns. 
 In addition, numerous studies not reviewed for this thesis have shown that it may be 
possible to shorten the antibiotic treatment regimens from a 10-day median to a 5-day median for 
some diseases without reducing their effectiveness (Aminov 2010; Spellberg 2016).  That 
suggests conducting experiments for additional infections means doctors will be able to prescribe 
fewer antibiotics for shorter therapy durations and reduce the selective pressures towards 
developing resistance among any surviving infectious bacteria.  Innovative treatments based on a 
patient-centric framework may be the best path forwards for safeguarding the utility of 
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remaining antibiotics against the dangers of bacteria developing resistance from overuse of these 
important drugs.  These patient-focused treatments could also include newer point-of-care 
diagnostics so that the physician or doctor can better understand what is actually occurring 
within the patient’s body besides simply relying on a patient’s ability to describe their illness, 
and using that information to determine whether an antibiotic prescription is necessary for the 
patient to recover or whether a different therapy would be more appropriate. 
 At the current stage of drug availability, having a national database compiling infections 
for which certain antibiotics could be used while others are resistant would be a significant step 
forwards to ensuring proper usage of available antibacterial drugs.  Studies conducted in the 
European Union based on a similar idea have shown a strong correlation between the rate of per 
capita antibiotic consumption and the rate of resistance observed among their member 
populations (Bartlett 2013).  This makes sense, as increased usage of antibiotics provides the 
bacteria with increased opportunities to experience the antibacterial agents and evolve resistant 
genes to counteract the agents.  With the European Union, the countries that showed better care 
for the overall usage of antibiotics and invested more effort to managing and regulating their 
availability, such as the Netherlands and more recently France, were found to be better stewards 
of antibiotics and showed decreased overall presence of resistance in bacteria when compared to 
countries like Greece that did not properly care for regulating their antibiotics usage (Bartlett 
2013).  These ideas of antibiotic stewardship should be applied in the United States as well, and 
together with public education about proper usage of antibacterial drugs will reduce the 
evolutionary rate of resistance to current antibiotics. 
 Any additional studies of antibiotic effectiveness are not likely to be very useful in 
practice, however, if regulatory approval standards are not accommodating of constantly 
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evolving needs towards treating bacterial infections.  While the current stance for conducting 
clinical trials treat bacterial infections as simple cases with very little consideration for 
predisposed factors that may affect antibiotic efficacy, doctors are left uncertain about how 
effective the antibiotic agent may actually be for their particular patient who perhaps has a 
history of illnesses and had already tried a similar antibiotic, and often find no guidance for 
interpreting the results of FDA-required clinical trials for using the antibiotic in real-world 
scenarios (Bartlett 2013; Spellberg 2010).  The standards should be clarified to allow for more 
extensive and more comprehensive trials that would account for additional factors beyond the 
basic question of “does this antibiotic agent work” on a particular subset of the population, 
including factors relating to whether race or age or medical history may play a part in 
determining their effectiveness.  These clarifications could involve a panel of antibiotics experts, 
public health specialists, doctors, and operations researchers working together to find a balance 
between clear indications of clinical trial opportunities for focusing study of the antimicrobial 
agent’s effects on certain diseased patients compared to a broader understanding of its potential 
overall efficacy in more complicated real-world scenarios.  The panel may consider approaching 
this work by examining current standards and determining which statistical-based requirements 
stifle progress for current experimental antibiotics but could be loosened to support future trials, 
as exemplified through requiring placebo-controlled trials for new pneumonia antibiotic 
treatments (Spellberg 2015).  Through the clarified regulatory standards, future clinical trials 
would be better able to answer more questions that doctors and physicians currently have about 
the efficacy of real-world usage for the new antibiotics. 
 Regulations related to antibiotic usage for farm animals and among the environment 
overall must also be tightened in a manner similar to what the European Union has already 
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implemented as its standards, with a focus on treating infections after they have definitively 
sickened some animals rather than trying to prevent illnesses from occurring at all (Merriman 
2016; Bartlett 2013).  A reduction in agricultural use could thus reduce the proliferation of 
antibiotic-resistant bacteria by limiting the potential sources of developing resistance, where a 
1976 study by microbiologist Stewart Levy showed that antibiotic-resistant bacteria were 
spreading around the farm and even to nearby humans that were not consuming those antibiotic 
drugs (The Iniquiry 2016).  Because farm animals are such a major consumer of antibiotic agents, 
it will require vast improvements in regulating their usage by the agriculture industry before any 
significant impact will be observed for overall development of antibiotic resistance.  These 
improvements should mirror European Union standards, where antibiotics are available only for 
treating diseases instead of working as “growth-promoters” by suppressing potential infections, 
and ideally would extend towards providing better care for the animals so that they may grow to 
similar sizes with only minor usage of antibiotic agents.  Through this method, fewer cases of 
resistance will develop before humans can really utilize some of the modern antibiotics while 
also limiting the current chances, however seemingly small, that a superbug or similar drug-
resistant infection wipes out the population of multiple farms. 
 Even if all the prior suggestions are fully implemented, humankind still needs to identify 
and isolate additional genuinely new sources of antimicrobial agents to ward off many of the 
issues posed by antibiotic resistance.  Thus, the second set of ideas is aimed towards helping 
scientists to realize new opportunities for attacking bacterial infections, which is the primary 
purpose of using antibiotic agents.  Although it remains difficult to replicate any bacteria 
originating from “exotic” parts of the world, new technologies such as a diffusion chamber 
(Merriman 2016) can assist by closely recreating the original environments for the bacteria and 
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allowing scientists to study them under a controlled situation.  Other opportunities exist from 
studying ecological niches beyond the traditional soil-based fungi (Aminov 2010), or possibly 
even attacking a completely synthetic approach based on examining genome sequences of the 
infectious bacteria.  It should be possible to understand the unique biochemical compositions 
exhibited by a variety of bacteria strains, either by knowing its genome sequence or by using 
polymerase chain reaction (PCR) machines to examine them, so although a synthetic approach 
may have a broader search region than simply examining natural sources it would also offer 
more opportunities to consider different approaches for targeting and attacking bacteria that may 
not have naturally been evolved.  Admittedly, other challenges to applying the synthesis-based 
option include ensuring sufficient supply of chemical and biological compounds to create new 
potential antibiotic agents and test their efficacy within a controlled experiment, so this may take 
more time and resources to implement compared to the other nature-based sourcing suggestions 
provided. 
 Beyond finding exotic sources of new antibiotics, scientists should investigate the 
possibility of developing therapies that operate on a collective population scale instead of an 
individual cell scale due to their capabilities of signaling and transferring genes to other bacterial 
cells. The traditional view of bacteria was one considering them to be simple singular-celled 
organisms, so antibiotics were targeted to attack the disease primarily by killing off cells or by 
restricting its ability to reproduce and spread.  Targeting the population scale could instead focus 
on attacking the signaling methods or other related systems and become a more effective 
antimicrobial agent as the selective pressure on bacteria to adapt drug resistance in this manner 
would be much lower than the selective pressure to adapt against directly lethal drugs, if not 
completely reduced.  In addition, reframing our understanding of bacterial diseases and how the 
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human body has already evolved to handle infections may support development of novel 
therapies and treatment approaches that allow the body to work through combatting the bacteria 
with some support of antibacterial drugs.  These developments would also improve the 
capabilities of point-of-care diagnostics and provide physicians with more choices to consider for 
treating their patient’s illness instead of simply prescribing a round of antibiotic therapy due to 
there being no other option. 
 The research necessary for developing new antibacterial agents can be funded through 
some economic incentives to pharmaceutical companies, either as push incentives supporting the 
research and development stages, such as through tax breaks, or as pull incentives allowing for 
extended sales protection.  Some models examined by Spellberg et al. showed that when the time 
value of money is accounted for, a pull incentive allowing for five years of extended sales 
exclusivity after the normal twenty year patent term expires would generate equivalent economic 
value as a push incentive investment of $43 million right away, or equivalent to providing $6.25 
million each year during the typical thirteen-year research and development period of antibiotic 
drugs (Spellberg 2012).  The tradeoffs here come from pull incentives benefitting solely the 
company and depending on the premise of increased sales during extended exclusivity, which go 
against the stewardship need for properly protecting and limiting usage of antibiotics as short-
term treatments, while push incentives likely will require considerable public force of will to 
dedicate the tax breaks or other form of economic support towards developing new antibiotic 
drugs rather than investing in other public works projects such as education and transportation.  
Other options for incentivizing research and development of antibiotic drugs could include 
working through public-private partnerships as well as using the defense contractor funding 
model, where government agencies fund part of the costs for research and development in 
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exchange for telling the contractor companies what public needs the research should focus on 
(Bartlett 2013; Spellberg 2015).  This option is likely the most prudent opportunity to emphasize 
the public trust nature of antibiotics as a whole and support the notion that even though private 
companies are putting forth much of the effort to conduct research and development of new 
antibiotics, the resulting drugs need to be cared for per proper stewardship concerns as a 
publically-shared commodity with distribution regulated by patients being given doctor 
prescriptions suited with an effective antibiotic choice and at an efficient dosage for treatment of 
a properly diagnosed disease, instead of being considered as simply another set of medical 
supplies available that the general public can stock at home for unexpected illnesses. 
 
Conclusions 
 This thesis examined the history of antibiotics and suggested a consortium of methods for 
preserving their capabilities and efficacy, but the research work will never fully be complete for 
humanity since bacteria and evolution are such fundamental aspects of nature.  So long as 
humankind desires to maintain the current style of medical care, with antibiotics usage prevalent 
across many fields as a preventative measure against potential diseases, the race to find the next 
big drug before bacteria develop resistance to the current one continues moving onwards with 
significant economic impacts.  Even on a population level, there are still many factors and 
questions about antibiotics that remain unknown, especially with regards to how antibiotics and 
their corresponding resistance effects the environment as a whole – can they spread from humans 
back into the food chain, for example, or would they readily disseminate across the broader 
world of nature and create new superbugs among bacteria that scientists currently do not know 
about, for another.  Should this thesis help influence a party’s decision for studying antibiotics 
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and managing the stewardship of these miracle drugs, future work in this area could examine 
these interactions of antibiotic resistance among the environment at large or how bacteria 
manage to coordinate on a population scale, as well as the possibility of conducting 
macroeconomic cost-benefit analyses for implementing any of the multitude of policies aimed 
towards preserving antibiotics.  The work geared for understanding microbes and attacking 
agents is never-ending due to the continuous evolution of resistance, but it is imperative for 
humanity to take important steps now to help preserve the capabilities of current antibiotics 
while waiting for new ones to be discovered and produced.  Otherwise, humankind may fall 
down to a world comprised of shorter lifespans and “simple” illnesses becoming deadly to 
humans once again, losing much of the medical progress and quality of life advancements that 
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